Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

French healthcare company Sanofi on Thursday said it was ending a programme evaluating tusamitamab ravtansine related to the treatment of types of lung cancer.

Sanofi to end cancer research programme evaluating tusamitamab ravtansine

Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint CARMEN-LC03 trial did not meet dual primary endpoint of improving progression-free survival; tusamitamab ravtansine clinical development program will be discontinued Sanofi reinforces commitment to broader oncology development program including CEACAM5-directed antibody drug conjugates (ADC) with additional anticipated trials PARIS, December 21, 2023. Sanofi is discontinuing the global clinical development program of tusamitamab ravtansine.

Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint

Sanofi's Q3 results were lower than expected, causing pressure on its share price. The company reported a decrease in revenue, largely due to FX effects, but saw an increase in underlying revenue at constant exchange rates. Sanofi plans to invest in its biopharma business, streamline operations, and cut costs by €2 billion by 2025.

Sanofi: Expect A Weak 2024 Leading Up To A Strong 2025

Innate Pharma SA

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi (NASDAQ: SNY) announced today that Sanofi has exercised its option to license a natural killer (NK) cell engager program in solid tumors from Innate's ANKET® (Antibody-based NK Cell Engager Therapeutics) platform pursuant to the terms of the research collaboration and license agreement signed in December 2022. Following a research collaboration period, Sanofi will be responsible.

Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi

Arcturus Therapeutics

Catalyst Pharmaceuticals

Harmony Biosciences Holdings

MacroGenics

Pfizer

Voyager Therapeutics

With so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks. Just like advancements in the digital ecosystem, society will continue to invest in clinical breakthrough stocks in the hopes of forwarding treatments to vexing conditions and diseases.

7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar

French healthcare company Sanofi on Friday said the European Medicines Agency (EMA) had issued a positive opinion of its treatment for sleeping sickness, also called rhodesiense.

Sanofi gets positive EMA opinion for sleeping sickness treatment

Availability of the Q4 2023 Memorandum for modelling purposes Paris, France – December 15, 2023. Sanofi announced today that its Q4 2023 Memorandum for modelling purposes is available on the "Investors" page of the company's website: https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/q4-results-2023 As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results.

Press Release: Availability of the Q4 2023 Memorandum for modelling purposes

EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa Paris, Geneva and Nairobi. December 15, 2023.

Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa

AstraZeneca

The makers of a respiratory syncytial virus (RSV) immunization for infants that has been in tight supply will deliver an additional 230,000 doses in January, the White House said on Thursday, after U.S. government officials met with the companies to discuss meeting winter demand.

AstraZeneca, Sanofi to supply 230,000 more RSV infant shots to US market

Sanofi (SNY) decides to end the licensing deal with Maze Therapeutics for MZE001, a phase II ready oral tablet for Pompe disease, due to the FTC's decision to block the deal.

Sanofi (SNY) Terminates Pompe Disease Deal as FTC Objects

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced the U.S. Federal Trade Commission (FTC) has filed a complaint seeking to block Sanofi's exclusive worldwide license agreement for Maze's glycogen synthase 1 (GYS1) program, including clinical candidate MZE001, which is in development for the treatment of Pompe disease and other potential indications. The agreement was originally announced in May 2.

Maze Therapeutics Announces FTC Action Seeking to Block Collaboration and License Agreement with Sanofi Regarding MZE001, a Potential Oral Substrate Reduction Therapy for Pompe Disease

Sanofi SA SAN, +1.94% said late Monday it will scuttle an agreement with biotech Maze Therapeutics Inc. after federal trade regulators sought to block it, saying the deal would eliminate competition for the treatment of a rare genetic condition. “We respectfully disagree with the action by the [Federal Trade Commission] which also delays potential advancements that could impact the lives of patients,” Sanofi said.

Sanofi ends licensing deal with Maze Therapeutics after FTC action

Sanofi said on Monday it was terminating a deal to exclusively license a drug that Maze Therapeutics is developing to treat Pompe disease because of objections from the U.S. government.

Sanofi terminates deal on drug license after US FTC objects

Statement on FTC challenge to proposed license agreement with Maze Therapeutics Paris, December 11, 2023. Sanofi is disappointed with the Federal Trade Commission's announcement that it is seeking a preliminary injunction against a proposed licensing agreement between Sanofi and Maze Therapeutics.

Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics

Amgen

Bristol-Myers

Gilead Sciences

Merck

Novo Nordisk

Novartis

This biotech giant remains a top stock for investors to buy and pays a solid 3.13% dividend.

6 Health Care Dividend Stocks To By Hand Over Fist

Sarclisa ® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone Phase 3 data showed Sarclisa added to carfilzomib, lenalidomide and dexamethasone (KRd) in patients with newly diagnosed, transplant-eligible multiple myeloma resulted in 77% of patients achieving minimal residual disease (MRD) negativity after consolidation therapy, detected with a sensitivity of 10-5 MRD negativity rate measured at a sensitivity of 10-6 was 67% for Sarclisa combination therapy Results shared during oral presentation at ASH 2023 plenary scientific session PARIS, December 10, 2023. The Phase 3 trial investigating Sarclisa® (isatuximab) in combination with carfilzomib, lenalidomide and dexamethasone (KRd) showed a statistically significant improvement in the rate of minimal residual disease (MRD) negativity, compared with KRd alone, after autologous stem cell transplant (ASCT) consolidation in transplant-eligible patients with newly diagnosed multiple myeloma (MM).

Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone

CAIRO and PARIS , Dec. 10, 2023 /PRNewswire/ -- Sanofi and Minapharm announce the signing of an exclusive Manufacturing and Supply Agreement for the localization of the full range of its flagship market leader product, Clexane®. The agreement between Sanofi, a global pharmaceutical company and Egypt's Minapharm, a regional Biotech company with wholly owned subsidiaries in Cairo and Berlin, boosts Egypt's national localization strategy of biopharmaceutical manufacturing.

Sanofi and Minapharm Sign an Exclusive Agreement for Localizing the manufacture of Clexane®

Sanofi (SNY) aims to generate annual sales of over 10 billion euros by 2030, driven by recently launched and potential new products. It intends to enhance R&D focus to become a market leader in immunology.

Sanofi (SNY) Posts Upbeat Long-Term Outlook, Enhances R&D Focus

Sanofi said it would spend close to 700 million euros ($754 million) more on drugs development next year, specifying for the first time an increase in costs that roiled investors and triggered a sell-off in the stock in late October.

Sanofi to boost drug development spend by 700 mln euros in 2024

Sarclisa ® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant

Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant

Sanofi said on Thursday it will focus on 12 potential blockbuster drug candidates and prioritise development in immunology, as it faces investor pressure after abandoning 2025 margin targets while boosting research and development spending.

Sanofi to focus on 12 blockbuster drug candidates, immunology pipeline

R&D Day Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology Details strong pipeline including Sanofi's record 12 blockbuster opportunities under clinical evaluation: 9 innovative medicines and vaccines with €2 to 5 billion peak sales potential, and 3 ‘pipeline-in-a-product' assets with a potential of over €5 billion peak sales Strategic transformation through R&D features potential multi-indication assets such as amlitelimab, frexalimab and the oral TNFR1si intended to address unmet patient needs in markets with low penetration of advanced therapies Enhanced R&D focus aims to deliver a 50% increase in Phase 3 trials in 2024 and 2025 as well as 25 mid- to late-stage read-outs over the next 2 years Ambition to become an immunology powerhouse driven by recent and future launched pharma assets, generating over €10 billion in annual sales by 2030, in addition to the strong growth of Dupixent and Vaccines Paris, December 6, 2023. Today Sanofi is hosting an Investor R&D Event in New York providing updates and insight into its innovative pipeline and new growth drivers.

Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology

PARIS--(BUSINESS WIRE)--AQEMIA announces a major multi-year collaboration of $140 million with Sanofi.

AQEMIA Announces a Major Multi-year Collaboration of $140 Million With Sanofi

Sanofi's CEO is under pressure to tell investors how much more he will spend on research and development (R&D) and what the likely pay-offs will be, as he seeks to boost a pipeline of future drugs and restore shareholder trust.

Sanofi CEO under pressure to woo investors after spending shock

Caterpillar

Prologis

Here are three undervalued stocks with promising growth potential and high-quality A-rated balance sheets. It's just one of three incredible opportunities that combine to create a 16% annual return potential for the next decade, 350%, almost 3X more than the S&P. These are wide moat industry legends, blue-chip bargains hiding in plain sight.

News for Sanofi Stock (SNY)